Opportunity

SAM #75N98027R00020

NIH market research for biologics reagent generation services

Buyer

NIDA

Posted

November 16, 2026

Respond By

November 30, 2026

Identifier

75N98027R00020

NAICS

325411, 541714, 325414, 325413

NIH is researching sources for a potential 10-year effort to generate reagents for biologics bioanalytical method development. - Government buyer: National Institutes of Health (NIH), through the National Center for Advancing Translational Sciences (NCATS), Therapeutic Development Branch, Division of Preclinical Innovation. - Potential requirement: Reagent Generation for Bioanalytical Method Development on Biologics Therapeutics, also known as TRND 6. - Services sought: Generate and characterize polyclonal and monoclonal anti-drug antibodies, including neutralizing antibodies, and deliver purified reagents for method development and testing. - Reagents may support quantification of biologic drugs in plasma, serum, tissue homogenates, and other biological samples. - For gene-based therapies, targets may include the therapeutic protein and delivery carriers such as vector capsids. - An estimated 10–50 mg of each reagent may be needed; the number of reagents is not specified. - OEMs and vendors: No OEMs or vendors are named in the opportunity materials. - Notable requirement: The agency is seeking capability information for a potential indefinite-delivery, indefinite-quantity (IDIQ) effort; specific reagent quantities and task-order requirements are not established.

Description

Title:  Reagent Generation for Bioanalytical Method Development on Biologics Therapeutics 

This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential requirement.

This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition.  It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract.  Responses will not be considered as proposals or quotes.  No award will be made as a result of this notice.  The Government will NOT be responsible for any costs incurred by the respondents to this notice.  This notice is strictly for research and information purposes only.

The Government is especially interested in determining (1) the availability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition (5) commercial product and services availability. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible.

Background:  The Therapeutic Development Branch (TDB) within the Division of Preclinical Innovation (DPI) at National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) conducts translational research in the area of human therapeutics development by moving small molecule and biologic drug candidates forward in the drug development pipeline. Upon reaching predetermined milestones, TDB hands off clinical candidates to external partners to bring these novel therapies to patients. In addition to developing new candidate drugs, TDB seeks to advance the entire field of drug discovery and development by encouraging scientific and technological innovations aimed at improving success rates in the crucial preclinical stage of drug development. The TDB model is to operate as a comprehensive small molecule and biologics drug development organization, moving therapeutic candidates through each phase of the preclinical development process until an Investigational New Drug (IND) application is filed with the US Food and Drug Administration (FDA). TDB conducts drug development as collaborations, with therapeutic candidates originating from academia, industry, non- profit foundations, or internally from NCATS and other NIH Institutes and Centers. TDB’s operational strategy is to combine the capabilities of in-house staff and collaborative partners with complementary support from contract research organizations (CROs). Each development program operates in a multi-disciplinary matrix team environment, with NCATS responsible for the overall planning and execution. 

Please see the attachment for more details.

View original listing